"Young Adult" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A person between 19 and 24 years of age.
| Descriptor ID |
D055815
|
| MeSH Number(s) |
M01.060.116.815
|
| Concept/Terms |
Young Adult- Young Adult
- Adult, Young
- Adults, Young
- Young Adults
|
Below are MeSH descriptors whose meaning is more general than "Young Adult".
Below are MeSH descriptors whose meaning is more specific than "Young Adult".
This graph shows the total number of publications written about "Young Adult" by people in this website by year, and whether "Young Adult" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 74 | 74 |
| 2009 | 0 | 247 | 247 |
| 2010 | 0 | 297 | 297 |
| 2011 | 0 | 318 | 318 |
| 2012 | 0 | 355 | 355 |
| 2013 | 0 | 457 | 457 |
| 2014 | 0 | 488 | 488 |
| 2015 | 0 | 499 | 499 |
| 2016 | 0 | 509 | 509 |
| 2017 | 0 | 505 | 505 |
| 2018 | 0 | 568 | 568 |
| 2019 | 0 | 534 | 534 |
| 2020 | 0 | 456 | 456 |
| 2021 | 0 | 342 | 342 |
| 2022 | 0 | 159 | 159 |
| 2023 | 0 | 155 | 155 |
| 2024 | 0 | 455 | 455 |
| 2025 | 0 | 326 | 326 |
| 2026 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Young Adult" by people in Profiles.
-
Risk biomarkers of chronic GVHD in children aged 10 years or younger and children/adults older than 10 years. Blood Adv. 2026 Jan 13; 10(1):168-180.
-
New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma. Blood Adv. 2026 Jan 13; 10(1):217-227.
-
Variants in DENND2B are associated with vulnerability for neurodevelopmental impairment, psychosis and catatonia. Brain. 2026 Jan 08; 149(1):252-261.
-
ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR STAGES 3 AND 4 PROLIFERATIVE SICKLE CELL RETINOPATHY RESULTS IN IMPROVED ANATOMICAL AND VISUAL OUTCOMES. Retina. 2026 Jan 01; 46(1):171-178.
-
Gonorrhea and Chlamydia Screening for Adolescents and Young Adults in Emergency Departments. JAMA Pediatr. 2025 Dec 01; 179(12):1343-1352.
-
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients. Clin Cancer Res. 2025 Dec 01; 31(23):5027-5036.
-
An analysis of diagnostic metabolomic profiles associated with hepatotoxicity during childhood ALL induction therapy. Blood Adv. 2025 Nov 25; 9(22):5802-5810.
-
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML. Blood. 2025 Nov 20; 146(21):2608-2611.
-
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR. Blood Adv. 2025 Nov 11; 9(21):5460-5472.
-
Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis. Blood Adv. 2025 Nov 11; 9(21):5489-5500.